Mogrify launched in February 2019 with $3.7m seed funding from Ahren Innovation Capital, 24Haymarket and CEO Darrin Disley and went on to secure grants from Innovate UK and SBRI Healthcare.
In October 2019 the Cambridge cell therapies startup announced it had raised an additional $16 million in Series A funding led by existing investor Ahren.
Parkwalk, the largest EIS growth fund manager, backing businesses with IP-protected innovations creating solutions to real-world challenges, 24Haymarket, a prolific early-stage investment syndicate in deep technology and the life sciences, and the University of Bristol Enterprise Fund III, also contributed to the new raise.
Mogrify is established in the Tuspark Bio-Innovation Centre at Cambridge Science Park with fully-kitted labs and is already working on its internal cell therapy programs for osteoarthritis, ocular and blood-related diseases.
The company has developed a proprietary direct cellular conversion technology which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
It is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.
Mogrify is commercialising its technology platform via a model that includes development and out-license of internally developed cell therapy assets, development and license of novel cell conversion IP, and the formation of joint-ventures to exploit the platform and/or novel cell conversion IP in non-core areas.
Mogrify’s leadership team is of significant commercial and scientific calibre. The company was founded by leading academics in bioinformatics, Professor Julian Gough (LMB, Cambridge, UK), cell reprogramming, Professor Jose Polo (Monash University, Melbourne, AU), and machine learning, Assistant Professor Owen Rackham (Duke-NUS, Singapore), and is chaired by Professor Steve Jackson – Frederick James Quick Professor of Biology (University of Cambridge), head of CRUK Laboratories (Gurdon Institute), founder of KuDOS Pharmaceuticals, co-inventor of Olaparib (Lynparza®), founder of Mission Therapeutics and co-founder of Ahren.